GT Biopharma (NASDAQ:GTBPNASDAQ:GTBP) has developed a proprietary protein technology that can identify, eliminate, and destroy deadly tumor cells in the body, potentially unlocking a $194 billion industry.

Read on to find out…

  • How this first-in class solution supercharges the body’s own cells to fight cancer…
  • How GT Biopharma (NASDAQ:GTBPNASDAQ:GTBP) successfully completed Phase 1 trials, proving concept and decreasing blast count (cancer cells) by up to 63%…
  • And how other immuno-oncology companies are getting scooped-up by big Pharma – in multi-million-to-BILLION-dollar deals.

Plus, you’ll get a sneak peek at the new, second generation of nanobody camelid treatments… which are proving more effective than Phase 1, and are moving towards clinical trials. 

And, you’ll discover how you can get a piece of the action today… before potentially positive results or an M&A deal hit the news.

Cancer.

It’s one of the most prevalent diseases in the world today.

According to the National Cancer Institute, almost 40% of the global population will be diagnosed with cancer at some point during their lifetime.

It’s also one of the leading causes of death worldwide… accounting for nearly 10 million deaths in 2020, or almost 1 out of every 6 deaths.1

And over the next 30 years, cancer is expected to cost the world a shocking 25.2 trillion dollars2 – in health care costs, lost labor, and lost savings. 

In the United States alone, it’s estimated that over $150 billion was spent on cancer care in 2018. This amount is only expected to rise as the population ages, and new, more expensive, treatments are adopted.

Biotechnology companies are chomping at the bit to find a low-cost solution – one that not only provides value – but also provides an effective treatment to one of the most terrifying diseases today…

Or even better, a new treatment that didn’t have any nasty side effects, like the ones that usually come with radiation and chemotherapy… 

And that’s why you should pay close attention to GT Biopharma (NASDAQ:GTBPNASDAQ:GTBP) and their team of experts.

“Natural Killer Cells: The Next Wave in Cancer Immunotherapy”3

GT Biopharma (NASDAQ:GTBPNASDAQ:GTBP), a clinical stage immuno-oncology company, is pioneering breakthrough immunotherapy treatments.

The company boosts the body’s own natural defense system, unleashing our own Natural Killer (NK) cells, to fight cancer.

Specifically, GT Biopharma’s proprietary protein technology, known as Trispecific Killer Engagers and trademarked TriKE®, is an NK cell engager.

It supercharges the NK cells already in the body – identifying, targeting, and binding to the tumor cell – and enhances their ability to kill cancer. 

In Phase 1 clinical trials, the company’s innovative technology established proof of concept and demonstrated reductions in blast count (cancer cells) by up to 63%. 

Since then, the company has been working to perfect its technology for supercharging the body’s natural immunity to attack cancerous cells for greater effectiveness.4

Now, GT Biopharma is on its second generation of nanobody camelid treatments. 

The company has created an entire series of new and improved immunotherapies, targeting different types of cancers.

GT Biopharma is now progressing the development of its TriKE molecule towards Phase 1 trials for these second-generation treatments, which include tests on leukemia, solid tumors, B-cell malignancies, and solid and hematological malignancies.5

So far in preclinical tests, these therapies have seen even better results.6 They’ve shown multiple advantages over the first generation, including:

  • Improved potency,
  • Enhanced binding ability to tumor cells, and
  • Commercial manufacturing capabilities.

And remember, this proprietary molecule is wholly owned by GT Biopharma.

Yet investors can now pick up shares in GTBP for less than $1…

Why Gilead Sciences was Willing to Pay $300 Million to License a Single Molecule

In May 2022, pharmaceutical giant Gilead Sciences paid a small immuno-oncology company, named Dragonfly:

  • $300 million…
  • a 20% royalty, and…
  • future milestone payments…

for a single pre-clinical molecule license.7

Similarly, to GT BioPharma, Dragonfly is developing a natural killer (NK) cell engager program that recruits NK cells to fight cancer.8 

Also, similarly to GT BioPharma, its new immunotherapy program is just now moving towards Phase 1 clinical trials9… 

But it’s not just Dragonfly (and its NK cell engager program) being scooped-up by Big Pharma… 

  • A year earlier, Sanofi paid $1 BILLION upfront and $225M in milestone payments to acquire the immuno-oncology company, Amunix Pharmaceuticals, and its portfolio of T-cell engagers.
  • In 2020, Roivant Sciences paid $60M upfront and promised $2 BILLION in potential milestone payments to Affimed for single pre-clinical molecule license.
  • In 2019, Sanofi licensed Affimed’s platform that generates both NK cells and T cells for $96M upfront, and an additional $5 BILLION in potential milestone payments.10

NK cell engagers could be the next generation of cancer treatments Big Pharma – and the world – have been waiting for!

And it’s not just an M&A deal that could accelerate this company’s valuation…

A Rapidly Growing Market

Per a recent study by Zion Market Research, the market for immuno-oncology drugs and therapies is expected to grow from $62.2 billion in 2020 to $194 billion by 2028, growing at a rate of 15% per year.11

According to this study, this massive growth is in part being driven by the rising research and development of advanced treatment options that are both more efficient and more effective – this is a paradigm shift from traditional chemotherapy treatments.  

Not surprisingly given the recent M&A activity, the largest share of the market is in North America – with much of the focus (72%) on treating cancer with monoclonal antibodies that attach themselves to lymphocytes such as NK cells.12

  • “A promising immunotherapy for cancer”13,
  • “The linchpin for successful cancer immunotherapy”14, and
  • “NK cell therapies at the forefront of cancer control”15.

With a growing industry and market size, and a clear direction towards researching NK cell engager treatments…

The company who pioneers a successful cancer treatment –could benefit enormously.

And GT Biopharma (NASDAQ:GTBPNASDAQ:GTBP) is positioned right in the center of it.

A Burgeoning Immuno-Oncology Industry

Cancer stocks are popular with investors for a reason…  

Almost 40% of the global population will be diagnosed with cancer at some point during their lives.16

Within the United States, approximately 18 million people are diagnosed with cancer annually – and 9.5 million die from the disease each year.17

It’s a devastating, far-reaching disease…

Yet despite these overwhelming statistics, the main therapies used to treat cancer today are more than 80 years old!  Chemotherapy became widely used in the 1940s,18 and radiation dates as far back as 189519.

However, innovative immuno-oncology companies like GT Biopharma (NASDAQ:GTBPNASDAQ:GTBP) are now looking to harness the body’s own natural defense system to unleash so-called Natural Killer (NK) cells to destroy tumors without the nasty side effects of chemotherapy or radiation.

The problem is, NK cells aren’t as abundant in the body as other cells – and once their primary target is destroyed, they’re exhausted and stop fighting.

As a result, many biotech companies developing immunotherapy treatments for cancer try to create new NK cells in a lab.

But this is a time-consuming, customized process that’s hugely expensive. It can cost upwards of millions of dollars per individual and is often very hard on patients.

Radically New Approach To Cancer Treatment

That’s why the approach of GT Biopharma (NASDAQ:GTBPNASDAQ:GTBP) and a tiny handful of other NK engager companies is so exciting.  This could be the breakthrough doctors have been in search of for decades.

Instead of trying to create new NK cells in a lab, GT Biopharma (NASDAQ:GTBPNASDAQ:GTBP) is using their proprietary protein technology (known as Trispecific Killer Engagers, trademarked TriKE®), to enhance our existing NK cell’s ability – so they can continue fighting and destroying cancer.

Originally developed by renowned immunologist and key opinion leader in the space Dr. Jeffrey Miller of the University of Minnesota Medical School, here’s how TriKE® works….

Like Microscopic, Laser-Guided Cruise Missiles Targeting Tumors

Delivered to a patient20 by infusion, the TriKE proteins are designed to trigger a “marker” on a patient’s tumor cells that then alerts the “natural killer” (NK) cells to attack the marked cells – and only the marked cells.

Unlike some conventional chemotherapy treatments, which often attack both healthy cells along with cancer cells, GT Biopharma’s TriKE agents are designed for precision.

They program NK cells to attack only tumor cells and to leave healthy cells intact.

In essence, GT Biopharma (NASDAQ:GTBPNASDAQ:GTBP) proprietary protein technology does four very important things:

  • Activates or awakens the body’s own NK cells;
  • Helps the NK cells precisely target tumor cells and only tumor cells;
  • Helps the NK cells to continue attackingtumor cells, one after the other, for months instead of days; and
  • Encourages the NK cells to multiply.

Putting the Body’s Defenders on Steroids

GT Biopharma’s “secret sauce” is the unique way it embeds a compound known as interleukin 15 (IL-15) within its TriKE® protein at 16 times21 the normal dose – and yet without significant side effects!

This potent blast of interleukin acts like a kind of cellular steroid, greatly prolonging the cancer-destroying ability of the NK cells and helping them to reproduce.

Data from recent clinical trials are encouraging. Stage 4 cancer patients saw virtually no side effects yet experienced significant reductions in their blast counts, the traditional measure for blood cancer, in their bodies.

Plus, the cost is relatively low:  As little as $100,000 per patient (covered by many insurance policies) instead of the $2 to $3 million per patient that other cell immunotherapies can charge.

New “First in Class” Approach With Virtually No Side Effects

The TriKE® protein is a genuinely new “first in class” approach that makes GT Biopharma (NASDAQ:GTBPNASDAQ:GTBP) stand out from its competitors, even those with market caps in the billions.

Unlike other companies GT Biopharma’s approach is not a cellular therapy but a simple drug.  That means patients don’t have to pay for – or suffer through – highly customized lab-created treatments.

What’s more, GT Biopharma (NASDAQ:GTBPNASDAQ:GTBP)’s immunotherapy has virtually no side effects – and that, too sets it apart. For patients suffering from end-stage cancer, the ability to tolerate treatments is an important consideration.

In addition, the TriKE® protein appears to naturally increase the number of NK cells within patients’ own bodies, potentially prolonging life.

A Small, Undiscovered Company with a Breakthrough Technology

Most important for investors, the market cap of other NK cell immunotherapy companies are in the hundreds of millions…

  • Century Therapeutics has a market cap of almost to $200 million,
  • Nkarata, Inc. has a market cap close to $230 million, and
  • Fate Therapeutics, which markets a therapy based on Dr. Miller’s earlier research, has a market cap of over $500 million.22

In contrast, GT Biopharma (NASDAQ:GTBPNASDAQ:GTBP) is currently sitting at market cap of only approximately $11 million…

Meanwhile, they’re developing some of Dr. Miller’s latest and most advanced immunotherapies.

That means early investors can acquire significant share positions at very low costs.

In addition, the company currently has not one, but SIX publicly disclosed TriKE® products in the pipeline.

GTB-3550 is the company’s first TriKE® product candidate that was evaluated in Phase 1 clinical trials for the treatment of acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and other CD33+ hematopoietic malignancies.  Phase 1 clinical trials were shown to be both safe and well-tolerated, as well as proving the molecule’s clinical concept and providing a framework for future product candidates.

GTB-3650 is a second-generation protein developed to treat AML and MDS.  It has replaced GTB-3550 and utilizes camelid nanobody technology.  GTB3650 has successfully completed pre-clinical trials and is in the good manufacturing process (GMP) stage, which is usually the last developmental milestone before progressing into phase 1 clinical trials.  

GTB-5550 TriKE® is a second-generation protein that induces NK cells to target B7H3+ tumors found in head and neck cancers, solid tumors, and certain types of bone marrow cancers.  It is also in the GMP stage and should begin clinical trials after GTB-3650. 

GT Biopharma has a number of additional nanobody pipelines, currently in pre-clinical trials.  These products focus on the treatment of B7H3 and HER2 tumors (which can be found in breast, bladder, pancreatic, ovarian, prostate and stomach cancers), B-cell malignancies, and hematological malignancies.

The company has also received patents for its proprietary natural killer (NK) cell engager, TriKE®, platform.  GT Biopharma has two U.S. patents for broad coverage of TriKE proteins targeting any antigen and TriKE proteins targeting HIV antigens.23  These patents cover the Company’s pipeline of clinical and non-clinical product candidates. 

GT Biopharma’s trademarked, patented, and wholly-owned proprietary platform and molecules could be the cancer solution the world has been waiting for… 

And if the company’s clinical trials show further promise, then all bets are off. 

This next generation of cancer treatments could unlock a $194 billion industry.  

Of course, it goes without saying that there are no guarantees in biotech investing.  Past performance is no guarantee of future results, and you should only speculate with money you can afford to lose.

Yet for investors who like stocks with a substantially high risk/reward ratio, then GT Biopharma (NASDAQ:GTBPNASDAQ:GTBP), currently selling for significantly less than $1 per share, may well be worth a close look.

For more information about GT Biopharma (NASDAQ:GTBPNASDAQ:GTBP), visit the company’s website or download its free investor presentation here.

1https://www.who.int/news-room/fact-sheets/detail/cancer
2 https://www.advisory.com/daily-briefing/2023/03/09/cancer-costs
3 https://pubmed.ncbi.nlm.nih.gov/35967421/
4 See GT_Biopharma_Corporate_Presentation_NOV_2022_GTB_Website, Slide 20.
5 Ibid., Slide 8
6 See GT_Biopharma_Corporate_Presentation_NOV_2022_GTB_Website, Slide 25:  “Cam16 IL15 camB7H3 TriKE ® Enables NK Cell Therapies More Effective.”
7 GT_Biopharma_Corporate_Presentation_NOV_2022_GTB_Website, Slide 29.
8 https://www.fiercebiotech.com/biotech/gilead-follows-big-pharma-peers-dragonflys-pond-300m-deal-nk-cell-engagers
9 DF7001, licensed by Gilead, prograss as of May 12, 2023 – https://www.dragonflytx.com/pipeline
10 Slide 29, https://d1io3yog0oux5.cloudfront.net/gtbiopharma/files/presentations/GT_Biopharma_Corporate_Presentation_DEC_2022_GTB_Website.pdf
11 https://www.zionmarketresearch.com/report/immuno-oncology-therapy-market
12 Ibid.
13 https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-022-03437-0
14 https://pubmed.ncbi.nlm.nih.gov/33995422/
15 https://pubmed.ncbi.nlm.nih.gov/31478911/
16 https://www.cancer.gov/about-cancer/understanding/statistics
17 https://www.cancer.gov/about-cancer/understanding/statistics
18 https://www.yalecancercenter.org/Answers_July_6_08_89594_5_v1.pdf
19 https://cancerres.aacrjournals.org/content/69/2/383
20 Verify Verified
21 Webinar video, Minute 12:00 ff.
22 as of May 12, 2023 per Yahoo Finance – https://finance.yahoo.com/quote/FATE?p=FATE&.tsrc=fin-srch
23 https://www.gtbiopharma.com/news-media/press-releases/detail/234/gt-biopharma-announces-issuance-of-two-new-patents-covering

IMPORTANT NOTICE AND DISCLAIMER

This article is a paid advertisement. Think Ink Marketing and its owners, managers, employees, and assigns (collectively “the Publisher”) is often paid by profiled companies or third parties to organize marketing campaigns, which include the creation and dissemination of these types of communications. In this case, in an effort to enhance public awareness of GT Biopharma (“GTBP”) and its securities, GTBP has provided the Publisher with a budget of approximately $40,000.00 USD to cover the costs associated with creating and distribution of this communication. The Publisher may retain any excess sums after expenses as its compensation. This compensation should be viewed as a major conflict with our ability to be unbiased. Readers should beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you receive this communication, which has the potential to hurt share prices. Frequently companies profiled in our articles experience a large increase in volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in volume and share price may likely occur. This communication is not, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security. Neither this communication nor the Publisher purport to provide a complete analysis of any company or its financial position. The Publisher is not, and does not purport to be, a broker-dealer or registered investment adviser. This communication is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the advertised company’s SEC, SEDAR and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk. Past performance does not guarantee future results. This communication is based on information generally available to the public and on interviews with company management, and does not (to the Publisher’s knowledge, as confirmed by GTBP ) contain any material, non-public information. The information on which it is based is believed to be reliable. Nevertheless, the Publisher cannot guarantee the accuracy or completeness of the information.

SHARE OWNERSHIP.

The Publisher does not own any shares of any profiled company GTBP and has no information concerning share ownership by others of in the profiled company GTBP . The Publisher cautions readers to beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you read the articles on this website and this has the potential to hurt share prices. Frequently companies profiled in such articles experience a large increase in volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases.

FORWARD LOOKING STATEMENTS.

This publication contains forward-looking statements, including statements regarding expected continual growth of the featured companies and/or industry. The Publisher notes that statements contained herein that look forward in time, which include everything other than historical information, involve risks and uncertainties that may affect the companies’ actual results of operations. Wherever possible, words such as “predicts”, “projects”, “targets”, “plans”, “expects”, “does not expect”, “budget”, “scheduled”, “estimates”, “forecasts”, “anticipate” or “does not anticipate”, “believe”, “intend” and similar expressions or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved, or the negative or grammatical variation thereof or other variations thereof, or comparable terminology have been used to identify forward-looking statements. These forward-looking statements include, among other things, statements relating to: (a) revenue generating potential with respect to GTBP industry; (b) market opportunity; (c) GTBP business plans and strategies; (d) services that GTBP intends to offer; (e) GTBP milestone projections and targets; (f) GTBP expectations regarding receipt of approval for regulatory applications; (g) GTBP intentions to expand into other jurisdictions including the timeline expectations relating to those expansion plans; and (h) GTBP expectations with regarding its ability to deliver shareholder value. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, as of the date of this document including, without limitation, assumptions about: (a) the ability to raise any necessary additional capital on reasonable terms to execute GTBP business plan; (b) that general business and economic conditions will not change in a material adverse manner; (c) GTBP ability to procure equipment and operating supplies in sufficient quantities and on a timely basis; (d) GTBP ability to enter into contractual arrangements; (e) the accuracy of budgeted costs and expenditures; (f) GTBP ability to attract and retain skilled personnel; (g) political and regulatory stability; (h) the receipt of governmental, regulatory and third-party approvals, licenses and permits on favorable terms; (i) changes in applicable legislation; (j) stability in financial and capital markets; and (k) expectations regarding the level of disruption as a result of COVID-19. Such forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of GTBP to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: (a) GTBP operations could be adversely affected by possible future government legislation, policies and controls or by changes in applicable laws and regulations; (b) public health crises such as the COVID-19 pandemic may adversely impact GTBP business; (c) the volatility of global capital markets; (d) political instability and changes to the regulations governing GTBP business operations (e) GTBP may be unable to implement its growth strategy; and (f) increased competition. Except as required by law, the Website Host undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future event or otherwise.

INDEMNIFICATION/RELEASE OF LIABILITY.

By reading this communication, you acknowledge that you have read and understand this disclaimer, and further that to the greatest extent permitted under law, you release the Publisher, its affiliates, assigns and successors from any and all liability, damages, and injury from this communication. You further warrant that you are solely responsible for any financial outcome that may come from your investment decisions.

INTELLECTUAL PROPERTY.

Think Ink Marketing is the Publisher’s trademark. All other trademarks used in this communication are the property of their respective trademark holders. The Publisher is not affiliated, connected, or associated with, and is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Publisher to any rights in any third-party trademarks.

IMPORTANT NOTICE AND DISCLAIMER

This website is owned and hosted by Market Tactic Media Ltd. Articles appearing on this website should be considered paid advertisements. Market Tactic Media Ltd. and its owners, managers, employees, and assigns (collectively “the Website Host”) is often paid by marketing companies to host websites on which articles profiling public companies are published. The Website Host has not been compensated by any of the profiled companies. The Website Host’s compensation for articles appearing on this website is as follows:

  • The Website Host has been paid approximately $500 per week while the advertisement campaign is active by Think Ink Marketing as compensation to host the article profiling GT Biopharma

SHARE OWNERSHIP

The Website Host does not own any shares of any profiled GT Biopharma and has no information concerning share ownership by others of any profiled companies and The Website Host cautions readers to beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you read the articles on this website and this has the potential to hurt share prices. Frequently companies profiled in such articles experience a large increase in volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases.

NO SECURITIES OFFERED

The articles on this website are not, and should not be construed to be, offers to sell or solicitations of an offer to buy any security. Neither the articles on this website nor the Website Host purport to provide a complete analysis of any GT Biopharma or its financial position. The Website Host is not, and does not purport to be, a broker-dealer or registered investment adviser. The articles on this website are not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the GT Biopharma. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the profiled GT Biopharma’s SEC and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk.

INDEMNIFICATION/RELEASE OF LIABILITY

By reading articles on this website, you acknowledge that you have read and understood this disclaimer, and further that to the greatest extent permitted under law, you release the Website Host, its affiliates, assigns and successors from any and all liability, damages, and injury from articles appearing on this website. You further warrant that you are solely responsible for any financial outcome that may come from your investment decisions.

LINKS TO THIRD PARTY WEBSITES

This website enables users to link to external websites not under the control of The Website Host. The Website Host has no control over the nature, content, and availability of those sites. The inclusion of any links is not intended as, and should not be construed as, a recommendation or endorsement of the content or views expressed on such external websites. The Website Host expressly disclaims any representation concerning the quality, safety, suitability, or reliability of any external websites and the content and materials contained in them. It is important for users to take necessary precautions, especially to ensure appropriate safety.

INTELLECTUAL PROPERTY

The Market Tactic is the Website Host’s trademark. All other trademarks used in this communication are the property of their respective trademark holders. The Website Host is not affiliated, connected, or associated with, and is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Website Host to any rights in any third-party trademarks.

FORWARD LOOKING INFORMATION

This document contains forward-looking information and forward-looking statements, within the meaning of applicable Canadian securities legislation, (collectively, “forward-looking statements”), which reflect expectations regarding GT Biopharma future growth, future business plans and opportunities, expected activities, and other statements about future events, results or performance. Wherever possible, words such as “predicts”, “projects”, “targets”, “plans”, “expects”, “does not expect”, “budget”, “scheduled”, “estimates”, “forecasts”, “anticipate” or “does not anticipate”, “believe”, “intend” and similar expressions or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved, or the negative or grammatical variation thereof or other variations thereof, or comparable terminology have been used to identify forward-looking statements. These forward-looking statements include, among other things, statements relating to: (a) revenue generating potential with respect to GT Biopharma industry; (b) market opportunity; (c) GT Biopharma business plans and strategies; (d) services that GT Biopharma intends to offer; (e) GT Biopharma milestone projections and targets; (f) GT Biopharma expectations regarding receipt of approval for regulatory applications; (g) GT Biopharma intentions to expand into other jurisdictions including the timeline expectations relating to those expansion plans; and (h) GT Biopharma expectations with regarding its ability to deliver shareholder value. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, as of the date of this document including, without limitation, assumptions about: (a) the ability to raise any necessary additional capital on reasonable terms to execute GT Biopharma business plan; (b) that general business and economic conditions will not change in a material adverse manner; (c) GT Biopharma ability to procure equipment and operating supplies in sufficient quantities and on a timely basis; (d) GT Biopharma ability to enter into contractual arrangements; (e) the accuracy of budgeted costs and expenditures; (f) GT Biopharma ability to attract and retain skilled personnel; (g) political and regulatory stability; (h) the receipt of governmental, regulatory and third-party approvals, licenses and permits on favorable terms; (i) changes in applicable legislation; (j) stability in financial and capital markets; and (k) expectations regarding the level of disruption as a result of COVID-19. Such forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of GT Biopharma to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: (a) GT Biopharma operations could be adversely affected by possible future government legislation, policies and controls or by changes in applicable laws and regulations; (b) public health crises such as the COVID-19 pandemic may adversely impact GT Biopharma business; (c) the volatility of global capital markets; (d) political instability and changes to the regulations governing GT Biopharma business operations (e) GT Biopharma may be unable to implement its growth strategy; and (f) increased competition. Except as required by law, the Website Host undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future event or otherwise.

HISTORICAL INFORMATION

Any graphs, tables or other information demonstrating the historical performance or current or historical attributes of GT Biopharma or any other entity contained in this document are intended only to illustrate historical performance or current or historical attributes of GT Biopharma or such entities and are not necessarily indicative of future performance of GT Biopharma or such entities.